Welcome to Kuiper Inc.
With over 30 years of international experience in cell and gene therapy, the founders of Kuiper Inc have established many of the standards used for regulatory development, approval, and commercialization of applied cell therapies.
Who We Are
Kuiper Inc. is a newly formed international biotech company that will facilitate breakthrough therapies transcending international borders.
Through strategic partnerships, a high proficiency in trade compliance, and strong local knowledge of both regulatory environments and health care economics, we plan to help fast track intellectual property to commercialization in foreign markets.
Learn more about the services Kuiper Inc. can offer you.
Product Candidate for Critical Limb Ischemia (CLI)
Kuiper plans to develop its product candidate, CLBS12, in Japan for conditional approval for regenerative medicine products.
Product Candidate for No Option Refractory Disabling Angina (NORDA)
CLBS14 has been studied in Phase 1, Phase 2, and Phase 3 randomized, double-blind placebo-controlled clinical trials.
Product Candidate for Coronary Microvascular Dysfunction (CMD)
Product is being studied in a 20-patient proof-of-concept ESCAPE-CMD Phase 2 study at two centers in the United States.